Global In Situ Hybridization Market, By Technology (Chromogenic In Situ Hybridization (CISH) and Fluorescence In Situ Hybridization (FISH)), Application (Immunology, Microbiology, Cancer Diagnostic, Neuroscience, and Infectious Disease), Type (DNA and RNA), Product (Instruments, Probes and Kits), End user (Biotechnology/Pharmaceutical Companies, Academic and Research Institutes, and Molecular Diagnostic Labs) – Industry Trends and Forecast to 2030.
In Situ Hybridization Market Analysis and Size
The incidence of ISH diagnosis can vary greatly depending on the specific disease or condition. For example, in cancer diagnosis, ISH techniques such as fluorescence in situ hybridization (FISH) are frequently used to detect genetic alterations in tumours, such as HER2 amplification in breast cancer or ALK rearrangements in lung cancer. In these specific cases, the incidence of ISH diagnosis would depend on the prevalence of these genetic alterations within the patient population.
Data Bridge Market Research analyses that the global in situ hybridization market, which was USD 1,003.50 million in 2022, would rocket up to USD 2,397.27 million by 2030, and is expected to undergo a CAGR of 11.5% during the forecast period. “Cancer Diagnostic” dominates the application segment of the in situ hybridization market owing to the growing demand for better diagnostic and treatment methods. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
In Situ Hybridization Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015-2020)
Revenue in USD Million, Volumes in Units, and Pricing in USD
By Technology (Chromogenic In Situ Hybridization (CISH) and Fluorescence In Situ Hybridization (FISH)), Application (Immunology, Microbiology, Cancer Diagnostic, Neuroscience, and Infectious Diseases), Type (DNA and RNA), Product (Instruments, Probes and Kits), End user (Biotechnology/Pharmaceutical Companies, Academic and Research Institutes, and Molecular Diagnostic Labs)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Danaher (U.S.), BioGenex (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), Bio SB (U.S.), Leica Biosystems Nussloch GmbH (Germany), Oxford Gene Technology (U.K.), Medtronic (Ireland), GENERAL ELECTRIC (U.S.), Siemens (Germany), Koninklijke Philips N.V. (Netherlands), IMRIS (Canada), NeuroLogica Corp. (U.S.) and Ziehm Imaging GmbH (Germany)
In situ hybridization refers to a laboratory technique where a probe used, and the probe is made with DNA or RNA. This probe is single-stranded containing moiety that can detect either chemically or radioactively. Then, single-stranded is hybridized and hybridization part comes in. This technique enables precise localization of a specific segment of nucleic acid within a histologic section.
Global In Situ Hybridization Market Dynamics
- Increasing Prevalence of Chronic Diseases
The rising incidence of chronic diseases, such as cancer, genetic disorder, and neurological disorders, is driving the demand for advanced diagnostic techniques like ISH. ISH enables the detection and analysis of specific genetic markers and alterations associated with these diseases, aiding in accurate diagnosis and personalized treatment strategies.
- Advancements in Molecular Biology and Genomics
The continuous advancements in molecular biology and genomics have expanded our understanding of genetic mechanisms underlying various diseases. ISH techniques have evolved to become more sensitive, specific, and multiplexed, enabling researchers and clinicians to study gene expression patterns, gene fusions, and chromosomal abnormalities with higher precision and accuracy.
- Increasing Research and Development Activities
The growing focus on biomedical research and drug discovery has driven the demand for advanced molecular techniques like ISH. Researchers are using ISH to study gene expression patterns, identify therapeutic targets, and validate drug candidates. The increasing R&D activities in the life sciences sector contribute to the growth of the global ISH market.
- Rising Healthcare Expenditure
Governments and healthcare organizations worldwide are increasing their healthcare expenditure, including investments in advanced diagnostic technologies. The allocation of funds towards improving healthcare infrastructure and access to advanced diagnostic tools is expected to drive the growth of the ISH market.
- Expansion of cancer diagnostics and research
Cancer is a leading application area for ISH, and the growing incidence of cancer worldwide provides a substantial opportunity for the ISH market. ISH techniques play a crucial role in identifying genetic alterations associated with different types of cancer, aiding in accurate diagnosis, prognosis, and treatment selection.
- Advancements in automation and digital pathology
The integration of ISH techniques with automated platforms and digital pathology solutions presents opportunities for increased efficiency, reproducibility, and scalability. Automated ISH systems can streamline the workflow, reduce hands-on time, and improve data analysis. Digital pathology enables remote viewing, sharing, and analysis of ISH results, facilitating collaboration and improving access to expert opinions.
- High cost of ISH assays
ISH assays can be expensive due to the need for specialized reagents, equipment, and expertise. The high cost of ISH assays can limit their adoption, particularly in resource-constrained settings or regions with limited healthcare budgets.
- Limited availability of skilled personnel
ISH techniques require skilled personnel who have expertise in molecular biology and histopathology. There is a shortage of trained laboratory technicians and pathologists with experience in ISH, which can limit the widespread adoption of ISH in routine diagnostics.
- Regulatory and reimbursement challenges
The regulatory landscape for ISH assays can vary across different regions, which can create challenges for market entry and product approvals. Additionally, reimbursement policies may not always adequately cover the costs of ISH testing, leading to financial constraints for healthcare providers and limited access for patients.
- Competition from alternative molecular techniques
ISH faces competition from other molecular techniques, such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and immunohistochemistry (IHC). These techniques offer their own advantages and may be preferred in certain applications, potentially impacting the demand for ISH.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the in situ hybridization market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
- In October 2021, Leica Biosystems announced the launch of the RNAscope VS Universal HRP Reagent Kit. This kit is designed to enhance the sensitivity of ISH assays, enabling researchers to detect low-abundance RNA targets with high specificity
- In June 2021, Bio-Techne announced the acquisition of Asuragen, a leader in molecular diagnostics and RNA-based technologies. This acquisition strengthens Bio-Techne's capabilities in the field of RNA-based diagnostics, including ISH
- In March 2021, PerkinElmer announced the launch of the Vectra Polaris II Automated Quantitative Pathology Imaging System. This system combines multiplexed immunohistochemistry (IHC) and ISH capabilities, enabling researchers to visualize and quantify multiple biomarkers in tissue samples
- In October 2020, Agilent Technologies introduced the GenetiSure Pre-Screen Kit, a solution for cytogenetic laboratories performing ISH-based pre-screening of clinical samples. This kit streamlines the workflow and improves the efficiency of ISH-based pre-screening for copy number variations.
Global In Situ Hybridization Market Scope
The market is segmented on the basis of technology, application, product, type, and end-user. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Chromogenic In Situ Hybridization (CISH)
- Fluorescence In Situ Hybridization (FISH)
- Cancer Diagnostic
- Infectious Diseases
- Probes and Kits
- Biotechnology/Pharmaceutical Companies
- Academic and Research Institutes
- Molecular Diagnostic Labs
Global In Situ Hybridization Market Regional Analysis/Insights
The global in situ hybridization market is analyzed and market size insights and trends are provided by country, technology, application, product, type, and end-user as referenced above.
The countries covered in the global in situ hybridization market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the global in situ hybridization market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having cancer, immunity diseases, etc.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for treatment and diagnosis of diseases like cancer, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global in situ hybridization market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the market.
Competitive Landscape and In Situ Hybridization Market Share Analysis
The global in situ hybridization market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global in situ hybridization market are:
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Merck KGaA (Germany)
- Agilent Technologies, Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Danaher (U.S.)
- BioGenex (U.S.)
- Advanced Cell Diagnostics, Inc. (U.S.)
- Bio SB (U.S.)
- Leica Biosystems Nussloch GmbH (Germany)
- Oxford Gene Technology (U.K.)
- Medtronic (Ireland)
- GENERAL ELECTRIC (U.S.)
- Siemens (Germany)
- Koninklijke Philips N.V. (Netherlands)
- IMRIS (Canada)
- NeuroLogica Corp. (U.S.)
- Ziehm Imaging GmbH (Germany)